Literature DB >> 23771122

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

Abdlsattar Zebary1, Katarina Omholt1, Remco van Doorn2, Paola Ghiorzo3, Katja Harbst4, Carolina Hertzman Johansson1, Veronica Höiom1, Göran Jönsson4, Dace Pjanova5, Susana Puig6, Giovanna B Scarra3, Mark Harland7, Håkan Olsson4, Suzanne Egyhazi Brage1, Jane Palmer8, Lena Kanter-Lewensohn1, Ismini Vassilaki9, Nicholas K Hayward8, Julia Newton-Bishop7, Nelleke A Gruis2, Johan Hansson10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23771122     DOI： 10.1038/jid.2013.270

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  8 in total

Review 1.  Genetics of melanoma predisposition.

Authors:  Nicholas K Hayward
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

2.  High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Elizabeth M Gillanders; Nicholas K Hayward; Marie-Francoise Avril; Esther Azizi; Giovanna Bianchi-Scarra; D Timothy Bishop; Brigitte Bressac-de Paillerets; William Bruno; Donato Calista; Lisa A Cannon Albright; Florence Demenais; David E Elder; Paola Ghiorzo; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M Mackie; Veronica Magnusson; Graham J Mann; Kristin Niendorf; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Femke A de Snoo; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Authors:  Katarina Omholt; Eva Grafström; Lena Kanter-Lewensohn; Johan Hansson; Boel K Ragnarsson-Olding
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

4.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Authors:  J-H Lee; J-W Choi; Y-S Kim
Journal:  Br J Dermatol       Date:  2011-03-21       Impact factor: 9.302

Review 5.  Familial melanoma.

Authors:  Johan Hansson
Journal:  Surg Clin North Am       Date:  2008-08       Impact factor: 2.741

6.  Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations.

Authors:  Malihe Eskandarpour; Jamileh Hashemi; Lena Kanter; Ulrik Ringborg; Anton Platz; Johan Hansson
Journal:  J Natl Cancer Inst       Date:  2003-06-04       Impact factor: 13.506

7.  Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.

Authors:  Braslav Jovanovic; Suzanne Egyhazi; Malihe Eskandarpour; Paola Ghiorzo; Jane M Palmer; Giovanna Bianchi Scarrà; Nicholas K Hayward; Johan Hansson
Journal:  J Invest Dermatol       Date:  2009-09-17       Impact factor: 8.551

Review 8.  The MAPK pathway in melanoma.

Authors:  Leslie A Fecher; Ravi K Amaravadi; Keith T Flaherty
Journal:  Curr Opin Oncol       Date:  2008-03       Impact factor: 3.645
  8 in total
  8 in total

1.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

Review 2.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

Review 3.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

Review 4.  Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.

Authors:  Efthymia Soura; Philip J Eliades; Kristen Shannon; Alexander J Stratigos; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2016-03       Impact factor: 11.527

5.  Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Authors:  Johan Staaf; Katja Harbst; Martin Lauss; Markus Ringnér; Anna Måsbäck; Jillian Howlin; Karin Jirström; Mark Harland; Abdlsattar Zebary; Jane M Palmer; Christian Ingvar; Håkan Olsson; Julia Newton-Bishop; Johan Hansson; Nicholas Hayward; Nelleke Gruis; Göran Jönsson
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

6.  Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

Authors:  William Bruno; Claudia Martinuzzi; Bruna Dalmasso; Virginia Andreotti; Lorenza Pastorino; Francesco Cabiddu; Marina Gualco; Francesco Spagnolo; Alberto Ballestrero; Paola Queirolo; Federica Grillo; Luca Mastracci; Paola Ghiorzo
Journal:  Oncotarget       Date:  2017-12-14

Review 7.  Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.

Authors:  Kristen Pauley; Ambreen Khan; Wendy Kohlmann; Joanne Jeter
Journal:  Front Oncol       Date:  2022-03-16       Impact factor: 6.244

8.  Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants.

Authors:  Francesco Spagnolo; Bruna Dalmasso; Enrica Tanda; Miriam Potrony; Susana Puig; Remco van Doorn; Ellen Kapiteijn; Paola Queirolo; Hildur Helgadottir; Paola Ghiorzo
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.